Effect of inulin supplementation on fecal and blood metabolome in alcohol use disorder patients: A randomised, controlled dietary intervention.
Clinical Nutrition ESPEN. 2025-04-01; 66: 361-371
DOI: 10.1016/j.clnesp.2025.01.046
Lire sur PubMed
https://www.bordeaux-neurocampus.fr/11919
Amadieu C(1), Ahmed H(2), Leclercq S(3), Koistinen V(4), Leyrolle Q(1), Stärkel
P(5), Bindels LB(6), Layé S(7), Neyrinck AM(8), Kärkkäinen O(9), De Timary
P(10), Hanhineva K(4), Delzenne NM(11).
Author information:
(1)Metabolism and Nutrition Research Group, Louvain Drug Research Institute,
UCLouvain, Université catholique de Louvain, Brussels, Belgium; Université de
Bordeaux, INRAE, Bordeaux INP, NutriNeurO, UMR 1286, F-33000 Bordeaux, France.
(2)Food Sciences Unit, Department of Life Technologies, University of Turku,
Turku, Finland.
(3)Laboratory of Nutritional Psychiatry, Institute of Neuroscience, UCLouvain,
Université catholique de Louvain, Brussels, Belgium.
(4)Food Sciences Unit, Department of Life Technologies, University of Turku,
Turku, Finland; School of Medicine, Institute of Public Health and Clinical
Nutrition, University of Eastern Finland, Kuopio, Finland.
(5)Department of Gastro-enterology, Cliniques Universitaires Saint Luc,
Brussels, Belgium.
(6)Metabolism and Nutrition Research Group, Louvain Drug Research Institute,
UCLouvain, Université catholique de Louvain, Brussels, Belgium; WELBIO
Department, WEL Research Institute, Wavre, Belgium.
(7)Université de Bordeaux, INRAE, Bordeaux INP, NutriNeurO, UMR 1286, F-33000
Bordeaux, France.
(8)Metabolism and Nutrition Research Group, Louvain Drug Research Institute,
UCLouvain, Université catholique de Louvain, Brussels, Belgium.
(9)School of Pharmacy, University of Eastern Finland, Kuopio, Finland.
(10)Department of Adult Psychiatry, Cliniques Universitaires Saint-Luc and
Institute of Neuroscience, UCLouvain, Université catholique de Louvain,
Brussels, Belgium.
(11)Metabolism and Nutrition Research Group, Louvain Drug Research Institute,
UCLouvain, Université catholique de Louvain, Brussels, Belgium. Electronic
address: .
BACKGROUND AND AIMS: Alcohol Use Disorder (AUD) is a psychiatric disorder
characterized notably by gut microbial dysbiosis and insufficient dietary fiber
(DF) intake. This study aims to investigate the effect of DF placebo-controlled
intervention in patients suffering from AUD during a three-week period of
alcohol withdrawal, in order to discover microbial-derived metabolites that
could be involved in metabolic and behavioral status.
METHODS: A randomized, double-blind, placebo-controlled study was performed with
50 AUD patients supplemented with inulin (prebiotic DF) or maltodextrin
(placebo) during 17 days. Fecal microbiota composition, plasma and fecal
metabolomics (liquid chromatography coupled to mass spectrometry), blood markers
of inflammation and hepatic alterations, and psychological assessment
(questionnaires) were analyzed before and after the intervention.
RESULTS: Fecal metabolomics revealed 14 metabolites significantly modified by
inulin versus placebo treatment (increased N8-acetylspermidine and decreased
indole-3-butyric acid, 5-amino valeric acid betaine (5-AVAB) and bile acids).
Thirteen plasma metabolites differentiated both treatments (higher levels of
long-chain fatty acids, medium-chain acylcarnitines and sphingomyelin species,
and reduced 3-methylhistidine by inulin versus placebo). Fecal Lachnoclostridium
correlated with 6 of the identified fecal metabolites, whereas plasma lipidic
moieties positively correlated with fecal Ruminococcus torques group and
Flavonifractor. Interestingly, parameters reflecting liver alterations inversely
correlated with sphingomyelin (SM 36:2).
CONCLUSIONS: Three weeks of inulin supplementation during alcohol withdrawal
leads to specific and different changes in the plasma and fecal metabolome of
AUD patients, some of these gut microbiota-related metabolites being correlated
with liver function.
TRIAL REGISTRATION: NCT03803709,
https://clinicaltrials.gov/ct2/show/NCT03803709.
Copyright © 2025 The Author(s). Published by Elsevier Ltd.. All rights reserved.
DOI: 10.1016/j.clnesp.2025.01.046
PMID: 39864520 [Indexed for MEDLINE]
Conflict of interest statement: Declaration of competing interest VK, OK and KH
are founders of Afekta Technologies Ltd. The other authors report no financial
interests or potential conflicts of interest.